Androgen Ablative Therapy of Advanced Hormone-dependent Prostate CarcinomaFASTNCT00930319
Effectiveness and Safety of Firmagon®
An observational study of Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, run by Ferring Pharmaceuticals at 230 sites in Germany.
Trial summary
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
- What is being tested?
- Firmagon given by prescription according to SPC
- How many people
- 676 participants
- Where
- 230 sitesGermany
- Study dates
- Jun 2009to Dec 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Advanced Hormone-dependent Prostate Carcinoma
Who may be able to join
- therapeutic need according to SPC
- written informed consent
Who cannot join
- contraindications according to SPC
Trial locations and contacts
230 sites in 1 country.
230 sites in 1 country
Germany230 sites
Investigational Site, Heinrich-Rieger-Str. 15
Aalen
Investigational Site, Weidenfelder Straße 1
Aalen
Investigational Site
Abensberg
Investigational Site
Ahaus
Investigational Site
Ahrensburg
Investigational Site
Alsdorf
Investigational Site
Alsfeld
Investigational Site
Altenburg
Investigational Site
Andernach
Investigational Site, Endresstraße 12
Ansbach
Investigational Site, Platenstraße 15
Ansbach
Investigational Site, Frölichstraße 13
Augsburg
Investigational Site, Prinzregentenstraße 4
Augsburg
Investigational Site
Bad Bergzaben
Investigational Site
Bad Godesberg
Investigational Site
Bad Marienberg
Investigational Site
Bad Oldesloe
Investigational Site
Bad Salzuflen
Investigational Site
Bad Schönborn
Investigational Site
Bad Wildungen
Investigational Site
Bautzen
Investigational Site, Albert-Einstein-Straße 2
Berlin
Investigational Site, Allee der Kosmonauten 47
Berlin
Investigational Site, Hohenzollerndamm 47a
Berlin
Investigational Site, Lipschitzallee 20
Berlin
Investigational Site, Mehrower Allee 22
Berlin
Investigational Site, Pasteurstraße 8
Berlin
Investigational Site, Rudolff-Seifert-Straße 11
Berlin
Investigational Site, Wisbyer Straße 16
Berlin
Investigational Site, Zeppelinring 7
Biberach
Investigational Site
Biedenkopf
Investigational Site, Elbeallee 83
Bielefeld
Investigational Site, Friedrich-Verleger Straße 5
Bielefeld
Investigational Site, Johannisstraße 43
Bielefeld
Investigational Site, Treppenstraße 3
Bielefeld
Investigational Site
Bitterfeld-Wolfen
Investigational Site
Bocholt
Investigational Site, St. Augustiner-Straße 21
Bonn
Investigational Site, Trierer Straße 70 - 72
Bonn
Investigational Site
Borken
Investigational Site
Bramsche
Investigational Site
Braunschweig
Investigational Site
Bremen
Investigational Site, Dr.-Franz-Mertens-Straße 8
Bremerhaven
Investigational Site, Georgstraße 44
Bremerhaven
Investigational Site
Bruchköbel
Investigational Site
Buchholz
Investigational Site
Bünde
Investigational Site
Burg
Investigational Site
Celle
Investigational Site, Carl-von-Ossietzky-Str. 151
Chemnitz
Investigational Site, Clausstraße 44
Chemnitz
Investigational Site, Flemmingstraße 1b
Chemnitz
Investigational Site, Unritzstraße 21 c
Chemnitz
Investigational Site
Coburg
Investigational Site, Custodistraße 3-17
Cologne
Investigational Site, Wilhelm-Ewald-Weg 1
Cologne
Investigational Site, Zeppelinstraße 1
Cologne
Investigational Site
Cottbus
Investigational Site, Karlstraße 30
Crailsheim
Investigational Site, Postplatz 2
Crailsheim
Investigational Site
Delitzsch
Investigational Site
Dessau
Investigational Site
Dillenburg
Investigational Site
Dinslaken
Investigational Site
Dortmund
Investigational Site
Dossenheim
Investigational Site
Dresden
Investigational Site, Kreuzstraße 3-5
Duisburg
Investigational Site, Königstraße 49
Duisburg
Investigational Site
Dülmen
Investigational Site
Düsseldorf
Investigational Site
Eisenhüttenstadt
Investigational Site, Geschwister-Scholl-Str. 6
Erfurt
Investigational Site, Juri-Gagarin-Ring 94
Erfurt
Investigational Site
Essen
Investigational Site
Finsterwalde
Investigational Site, Eschersheimer Landstr. 544
Frankfurt
Investigational Site, Im Steinbügel 13
Frankfurt
Investigational Site
Freiburg im Breisgau
Investigational Site
Freital
Investigational Site
Friedberg
Investigational Site
Friedrichshafen
Investigational Site, Arminstraße 24
Gelsenkirchen
Investigational Site, Feldmarkstraße 109
Gelsenkirchen
Investigational Site, Zum Ehrenmal 21
Gelsenkirchen
Investigational Site
Gera
Investigational Site
Giessen
Investigational Site, Helenenstraße 10-12
Gotha
Investigational Site, Schützenberg 10
Gotha
Investigational Site
Grimma
Investigational Site, Niemeyerstraße 23
Halle
Investigational Site, Reilstraße 129 a
Halle
Investigational Site, Steinweg 27
Halle
Investigational Site, Alte Holstenstraße 16
Hamburg
Investigational Site, Fuhlsbüttler Straße 182
Hamburg
Investigational Site, Grindelberg 3
Hamburg
Investigational Site, Herthastraße 12
Hamburg
Investigational Site, Tangstedter Landstraße 77
Hamburg
Investigational Site
Hattersheim
Investigational Site
Heidelberg
Investigational Site
Heilbronn
Investigational Site
Heinsberg
Investigational Site
Hennigsdorf
Investigational Site
Herford
Investigational Site, Enoch-Widmann-Straße 5
Hof
Investigational Site, Eppenreuther Straße 28
Hof
Investigational Site
Isenburg
Investigational Site
Jena
Investigational Site
Jülich
Investigational Site
Kaiserslautern
Investigational Site
Kamenz
Investigational Site
Kamp-Lintfort
Investigational Site
Karlsruhe
Investigational Site
Kempten
Investigational Site, Markt 11
Kiel
Investigational Site, Prüner Gang 15
Kiel
Investigational Site, Schulstraße 7
Kiel
Investigational Site
Kleinblittersdorf
Investigational Site, Friederikenstraße 30
Köthen
Investigational Site, Siebenbrünnenpromenade 6-7
Köthen
Investigational Site
Krefeld
Investigational Site
Kulmbach
Investigational Site
Lampertheim
Investigational Site
Langenau
Investigational Site
Lebach
Investigational Site
Leutkirch
Investigational Site
Lichtenfels
Investigational Site
Limbach-Oberfrohna
Investigational Site
Lübeck
Investigational Site
Lubnjow
Investigational Site
Ludwigshafen
Investigational Site
Lüneburg
Investigational Site
Lünen
Investigational Site
Magdeburg
Investigational Site
Mainz
Investigational Site, N7, 9
Mannheim
Investigational Site, Seckenheimer Hauptstraße 107
Mannheim
Investigational Site
Marburg
Investigational Site
Marl
Investigational Site
Mechernich
Investigational Site
Merseburg
Investigational Site
Merzig
Investigational Site
Michelstadt
Investigational Site
Miltenberg
Investigational Site
Moers
Investigational Site
Mölln
Investigational Site
Mörlenbach
Investigational Site
Mühlacker
Investigational Site
Mühlhausen
Investigational Site
Mühlheim
Investigational Site, Fürstenbergstraße 5
Münster
Investigational Site, Hohenzollernring 70
Münster
Investigational Site
Naumburg
Investigational Site
Neu-Ulm
Investigational Site
Neunkirchen
Investigational Site
Neuss
Investigational Site
Nienburg
Investigational Site
Norderstedt
Investigational Site, Bahnhofstraße 17
Nordhausen
Investigational Site, Bahnhofstraße 8
Nordhausen
Investigational Site, Am Museumsturm 4
Nordhorn
Investigational Site, Osnabrücker Straße 1
Nordhorn
Investigational Site, Am Stadtpark 2
Nuremberg
Investigational Site, Hefnersplatz 1
Nuremberg
Investigational Site, Kopernikusplatz 7
Nuremberg
Investigational Site
Obernburg
Investigational Site
Ochsenfurt
Investigational Site
Offenbach
Investigational Site
Osnabrück
Investigational Site
Paderborn
Investigational Site
Pasewalk
Investigational Site
Pirna-Copitz
Investigational Site
Prüm
Investigational Site
Pulheim
Investigational Site, Hindenburgstraße 10 A
Rastatt
Investigational Site, Kaiserstraße 7
Rastatt
Investigational Site, Gartenstraße 22
Ravensburg
Investigational Site, Grüner-Turm-Straße 7-9
Ravensburg
Investigational Site
Regensburg
Investigational Site
Remscheid
Investigational Site
Ribnitz-Damgarten
Investigational Site, Große Wasserstraße 2 - 3
Rostock
Investigational Site, Nobelstraße 51
Rostock
Investigational Site, Trelleborger Straße 10B
Rostock
Investigational Site
Röthenbach an der Pegnitz
Investigational Site
Rottweil
Investigational Site, Mainzer Straße 105
Saarbrücken
Investigational Site, Viktoriastraße 2
Saarbrücken
Investigational Site
Saarlouis
Investigational Site
Salzmünde
Investigational Site
Schönebeck
Investigational Site
Schwäbisch Gmünd
Investigational Site
Schwandorf in Bayern
Investigational Site
Schwerin
Investigational Site
Schwerte
Investigational Site
Senden
Investigational Site
Sindelfingen
Investigational Site
Sömmerda
Investigational Site, Kirchplatz 6a
Spremberg
Investigational Site, Lustgartenstraße 3
Spremberg
Investigational Site
Stockelsdorf
Investigational Site
Stolberg
Investigational Site
Stuttgart
Investigational Site
Sulzbach-Rosenberg
Investigational Site
Tettnang
Investigational Site
Tostedt
Investigational Site
Trier
Investigational Site
Troisdorf
Investigational Site
Überlingen
Investigational Site, Hirschstraße 22
Ulm
Investigational Site, Olgastraße 103
Ulm
Investigational Site, Olgastraße 139
Ulm
Investigational Site
Velbert
Investigational Site
Völklingen
Investigational Site
VS-Villingen
Investigational Site
Wangen
Investigational Site, Moosbürger Str. 13
Weiden
Investigational Site, Postgasse 1
Weiden
Investigational Site
Weißenfels
Investigational Site
Werl
Investigational Site
Werningerode
Investigational Site
Wesel
Investigational Site
Wiesbaden
Investigational Site
Wilhelmshaven
Investigational Site, Heinrich-Nordhoff-Straße 49
Wolfsburg
Investigational Site, Porschestraße 100
Wolfsburg
Investigational Site
Würselen
Investigational Site
Xanten
Investigational Site
Zerbst
About this study
Official title: Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.
- Being tested
- Firmagon given by prescription according to SPC
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Firmagon given by prescription according to SPCOther
Non-interventional,observational Firmagon given by prescription according to SPC
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC Receives: Other: Firmagon given by prescription according to SPC |
What is being measured
The primary outcome is the main question the study is designed to answer.
duration of the PSA progression-free survival
Measured: open (until therapy end or stop)
Secondary outcomes (3)
1. testosterone levels
Measured: open (until therapy end or stop)
2. number of ADRs and SUSARs
Measured: open (until therapy end or stop)
3. quality of life
Measured: open (until therapy end or stop)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2009 (estimated)
- Study startJun 2009
- Primary completionDec 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Androgen Ablative Therapy of Advanced Hormone-dependent Prostate CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 676 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ferring Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Ferring Arzneimittel GmbH
- Responsible party
- Sponsor
- Investigators
- Clinical Development Support, Study director, Ferring Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00930319
- Sponsor's protocol ID
- FE200486 CS41
- Acronym
- FAST
- Status last verified
- Mar 2014
- First submitted
- 29 Jun 2009
- Last updated
- 9 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
- ClinicalTrials.gov ID
- NCT00930319
- Acronym / sponsor ID
- FAST / FE200486 CS41
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 676 participants (actual)
- Lead sponsor
- Ferring PharmaceuticalsIndustry (pharma, biotech, devices)
- Collaborators
- Ferring Arzneimittel GmbH
- Study start
- Jun 2009
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 30 Jun 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA) progression during the Firmagon® therapy is to be documented and related to the testosterone values measured in the course of therapy (if available). Other clinical parameters, the patients' quality of life and the direct and indirect costs incurred by the medical care for the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In this context the medical outcome and the life quality are defined as effectiveness and benefit value parameters. Both the effectiveness under daily life circumstances and economic variables of the therapy can thus be shown and compared within an analysis of costs vs. benefits or costs vs. effectiveness.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Other: Firmagon given by prescription according to SPCPatients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Advanced Hormone-dependent Prostate Carcinoma
Key inclusion criteria (2 listed)
- therapeutic need according to SPC
- written informed consent
Key exclusion criteria (1 listed)
- contraindications according to SPC
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Firmagon given by prescription according to SPCNon-interventional,observational Firmagon given by prescription according to SPC | Other | 1 |
Primary outcome
duration of the PSA progression-free survival
Time frame: open (until therapy end or stop)
3 secondary outcomes
1. testosterone levels
Time frame: open (until therapy end or stop)
2. number of ADRs and SUSARs
Time frame: open (until therapy end or stop)
3. quality of life
Time frame: open (until therapy end or stop)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2023.
Related trials for Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
RecruitingPhase 2
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Development Support study director
Ferring Pharmaceuticals
230 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, run by Ferring Pharmaceuticals at 230 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 230 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
duration of the PSA progression-free survival (time frame: open (until therapy end or stop)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2023; AzTrials last refreshed its copy on 7 Nov 2026.